Please login to the form below

Not currently logged in
Email:
Password:

Mallinckrodt

This page shows the latest Mallinckrodt news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt doses first patient in muscular dystrophy trial

Mallinckrodt doses first patient in muscular dystrophy trial

Repurposed drug could help delay decline in muscle function. Mallinckrodt has kicked off a phase II trial of its Duchenne muscular dystrophy candidate, a repurposed drug used for years for inflammatory ... Mallinckrodt’s step forward comes shortly

Latest news

  • Mallinckrodt pays $1.2bn for Sucampo Pharma Mallinckrodt pays $1.2bn for Sucampo Pharma

    As 2017 drew to a close, Mallinckrodt signed a deal to buy Sucampo Pharma of the US - and its constipation drug Amitizia - for $1.2bn. ... Mallinckrodt is paying $18 per share for Sucampo and will also assume the company’s $360m debt under the terms of

  • Ireland's Mallinckrodt buys US regenerative medicine firm Ireland's Mallinckrodt buys US regenerative medicine firm

    Stratatech’s StrataGraft in phase III testing for burns treatment. Ireland's Mallinckrodt Pharma has continued its acquisitive streak with a deal to buy Stratatech, a US firm developing a biologic ... Mallinckrodt has not divulged the financial terms

  • Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase

    This is Mallinckrodt's second major acquisition this year designed to bolster its presence in hospitals. ... Mallinckrodt itself was spun off from Covidien in 2013 and has used acquisitions as a way of further its growth.

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    The muted response suggests some shareholders were hoping for a large-scale transformative deal - Mylan and Mallinckrodt had both been mentioned in dispatches as rumours of an a deal gathered last

  • Mallinckrodt cuts $5.6bn deal to buy Questcor Mallinckrodt cuts $5.6bn deal to buy Questcor

    Under the terms of the deal, Questcor's shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each share they own. ... Mallinckrodt investors seemed to be wary of the deal, however, and the Irish firm's share price went on the slide

More from news
Approximately 7 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Patent settlement, non-exclusive licence. 200. Mallinckrodt/Baxter International. RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant to control bleeding in surgery.

  • Pharma deals continue to slide Pharma deals continue to slide

    products. While this may not have been the reason behind GSK’s termination of its rare disease projects, it has not deterred Mallinckrodt from acquiring Infacare, a US company with a ... 469 (upfront 31). Infacare (US). Mallinckrodt (US/GB). Company

  • Deal Watch August 2016 Deal Watch August 2016

    Mallinckrodt (US) Nuclear Imaging business. IBA Molecular (BE). Asset acquisition. Diagnostic imaging products for use in nuclear medicine including molybdenum-99.

  • Pharma deals in August 2015 Pharma deals in August 2015

    30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐cell lymphoma [CTCL].

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    3, 500. Ikaria / Mallinckrodt. Company acquisition. Marketed critical care treatments incl.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Cogora

    Circassia. GE Healthcare. GlaxoSmithKline. Grunenthal. Indivior. Mallinckrodt. Mylan. Nestle. Novartis. Novo Nordisk.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics